Stock Report

Download full stock data and analysis for free Last Updated: 14-May-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

MyMD Pharmaceuticals Inc. (MYMD)

Stock Card factsheet share-fund-plan-icon

$1.60

up-down-arrow $0.27 (20.30%)

As on 25-Sep-2024 09:30EDT

Market cap

info icon

$4 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.4

Div. Yield

info icon

0 %

MyMD Pharmaceuticals (MYMD) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.31 High: 1.74

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $3 Mln

  • ROEROE information

    -1 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -0

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    2,370,420

10 Years Aggregate

CFO

$-79.29 Mln

EBITDA

$-103.36 Mln

Net Profit

$-95.96 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
MyMD Pharmaceuticals (MYMD)
-79.4 -17.9 -14.0 -90.5 -81.0 -70.3 -64.1
BSE Sensex*
-11.0 -1.9 -8.7 -7.1 6.7 9.1 11.5
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 25-Sep-2024  |  *As on 14-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
2018
2017
MyMD Pharmaceuticals (MYMD)
-77.5 -81.0 52.3 -37.8 -88.2 5.4 -92.9
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9 -9.7 11.7
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About MyMD Pharmaceuticals (MYMD)

MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a...  clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.  Read more

  • President, Chief Medical Officer & Director

    Dr. Christopher C. Chapman Jr., M.D.

  • President, Chief Medical Officer & Director

    Dr. Christopher C. Chapman Jr., M.D.

  • Headquarters

    Baltimore, MD

  • Website

    https://www.mymd.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for MyMD Pharmaceuticals (MYMD)

The share price of MyMD Pharmaceuticals Inc (MYMD) is $1.60 (NASDAQ) as of 25-Sep-2024 09:30 EDT. MyMD Pharmaceuticals Inc (MYMD) has given a return of -80.95% in the last 3 years.

Since, TTM earnings of MyMD Pharmaceuticals Inc (MYMD) is negative, P/E ratio is not available.
The P/B ratio of MyMD Pharmaceuticals Inc (MYMD) is 0.44 times as on 25-Sep-2024, a 90 discount to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
--
--
2022
--
--
2021
--
--
2020
--
--
2019
--
--

The 52-week high and low of MyMD Pharmaceuticals Inc (MYMD) are Rs -- and Rs -- as of 14-May-2026.

MyMD Pharmaceuticals Inc (MYMD) has a market capitalisation of $ 4 Mln as on 25-Sep-2024. As per SEBI classification, it is a Small Cap company.

Before investing in MyMD Pharmaceuticals Inc (MYMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.